Douglas Moss, MD
Obstetrics & Gynecology · New York, NYNPI 1114016631
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 8.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $872 and has fallen 60.8% since, to $342 in 2025. Among obstetrics & gynecology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celularity Inc.$336
- Evofem Biosciences, Inc.$316
- AbbVie$272
- Exact Sciences$271
- Amgen$253
- Millicent US Inc$227
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$3008%
- Food & beverage$3,48191%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celularity Inc. | 3 | $336 |
| Evofem Biosciences, Inc. | 23 | $316 |
| AbbVie | 14 | $272 |
| Exact Sciences | 15 | $271 |
| Amgen | 13 | $253 |
| Millicent US Inc | 12 | $227 |
| Therapeuticsmd, Inc. | 12 | $220 |
| Astellas Pharma US Inc | 23 | $192 |
| Shield Therapeutics Inc | 8 | $161 |
| Pfizer | 9 | $159 |
| Hologic Sales And Service, LLC | 7 | $146 |
| Vertical Pharmaceuticals, LLC | 7 | $114 |
| Scynexis, Inc. | 5 | $102 |
| Mayne Pharma Commercial LLC | 9 | $99 |
| Exeltis, USA Inc. | 5 | $95 |
| Sumitomo Pharma America, Inc. | 6 | $94 |
| Duchesnay USA Incorporated | 4 | $82 |
| Agile Therapeutics, Inc. | 5 | $82 |
| Daiichi Sankyo Inc. | 4 | $81 |
| IBSA Pharma Inc. | 4 | $67 |
| Myovant Sciences Inc. | 4 | $63 |
| Renovia Inc | 3 | $57 |
| Merck | 3 | $55 |
| Organon | 3 | $52 |
| GSK | 3 | $50 |
| AMAG Pharmaceuticals, Inc. | 2 | $31 |
| Avion Pharmaceuticals | 2 | $29 |
| Mission Pharmacal Company | 1 | $24 |
| Coopersurgical, Inc. | 1 | $23 |
| Roche Diagnostics Corporation | 1 | $16 |
| Medline Industries LP | 1 | $16 |
| Biogen | 1 | $15 |
| Dysis Medical, Inc. | 1 | $13 |
How this compares
$3,811 in reported general payments places this provider in the 90th percentile of 2,673 obstetrics & gynecology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 14 | $24,078 |
| MyrbetriqMirabegron | 21 | $11,942 |
| Estradiol | 176 | $10,139 |
| EstringEstradiol | 12 | $6,266 |
| YuvafemEstradiol | 29 | $5,032 |
| ImvexxyEstradiol | 18 | $4,722 |
| PremproEstrogen,con/M-Progest Acet | 13 | $3,161 |
| ProgesteroneProgesterone, Micronized | 97 | $3,099 |
| EstraceEstradiol | 11 | $2,721 |
| Raloxifene Hcl | 18 | $1,724 |
| Estradiol (Twice Weekly)Estradiol | 17 | $671 |
| ValacyclovirValacyclovir Hcl | 15 | $438 |
| Ibandronate Sodium | 19 | $311 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 19 | $311 |
| Nystatin | 19 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia | $253 | $24,07814 claims |
| Astellas Pharma US IncMyrbetriq | $192 | $11,94221 claims |
| PfizerEstring, Prempro | $159 | $9,42725 claims |
| Therapeuticsmd, Inc.Imvexxy | $220 | $4,72218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,673 obstetrics & gynecology providers in New York.
Other obstetrics & gynecology in New York
- Mary PolanNew York$862K
- Steven GoldsteinNew York$551K
- Veronica LernerNew York$368K
- Lisa EngNew York$219K
- Rachel MaschNew York$187K
- Amy PollackNew York$184K
- Jian Qun HuangNew York$160K
- Carolyn WesthoffNew York$143K
- Melanie MarinNew York$123K
- Amitasrigowri MurthyNew York$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.